Onco Actu du 29 juin 2015

	2. Etiologie
Viagra, Melanoma And The Problem With Big Data [Forbes] This story tells us more about the power (and danger) of so-called “big data” in healthcare than it does about the safety of Viagra.
	3.1 Tabac
E-cigarettes and health — here's what the evidence actually says [Vox] If you're a chronic smoker, e-cigarettes could be a less destructive way to get your nicotine fix. If you don't currently smoke at all, stay away from vaping; we still have no idea about its long-term health impact.
Consumers unclear about risks or benefits of e-cigarettes [Reuters] Researchers in Scotland interviewed 64 smokers and found little consensus about the potential benefits and harms of e-cigarettes, which may reflect division in the medical community on the appropriateness of promoting e-cigarettes as a safer alternative to the real thing.
	5. Traitements
Amgen Distributes Important Safety Updates on Prolia® [ASCO] Prolia® is a RANK ligand (RANKL) inhibitor used to treat osteoporosis in postmenopausal women who have high risk of bone fracture.
Overcoming Drug Resistance: The EGFR Enigma, Part 2 [CANCER RESEARCH Catalyst] A couple of studies discussed below have explored the feasibility of using first-in-class EGFR antibody therapies that are rationally designed to circumvent resistance to cetuximab and panitumumab in patients with solid cancers.
	5.12 Immunothérapies
Immunotherapy: 5 Ways to Stop Cancer [Cancer Research Institute] The Cancer Research Institute (CRI) has created a series of short, animated videos that explain the basics of the five most common types of immunotherapy in use.
	5.3 Traitements - FDA, EMA,...
Early dialogue to support development of medicines for children [EMA] The new initiative aims to encourage discussions on the paediatric needs that could be addressed with a specific medicine well before the submission of a paediatric investigation plan (PIP).
	5.3.4 Traitements - AMM (FDA, EMA)
Roche’s Perjeta recommended for approval in EU for use before surgery in HER2-positive early breast cancer [Roche] The Perjeta regimen is the first neoadjuvant (pre-surgery) breast cancer treatment recommended for approval in the EU based on the benefit in achieving pathological complete response (pCR).
Novartis scores recommendation from EMA for myeloma drug Farydak [FiercePharma] Novartis will have to work hard for its share of the pie as Kyprolis and Pomalyst trot out some promising numbers.
Novartis drug Farydak® recommended by CHMP for EU approval to treat multiple myeloma, providing patients a new mechanism of action [Novartis] CHMP positive opinion marks a key milestone toward panobinostat availability in the EU, aligning with recent US FDA approval.
First HDAC inhibitor for treatment of multiple myeloma recommended for approval in EU [EMA] Farydak (panobinostat) is the first cancer medicine that targets enzymes known as histone deacetylases or HDACs, which are involved in turning genes ‘on’ and ‘off’ within cells.
	5.4 Traitements - Economie
Merck cancer drugs and Sanofi, Amgen cardio meds have formularies on high alert [FiercePharma] "In the field of oncology, new anti-PD1 drugs (Opdivo and Keytruda) and Ibrance, a breast cancer treatment from Pfizer, will be the major drivers in continued double-digit drug spending increases."
	6. Lutte contre les cancers
Baroness Delyth Morgan appointed as chair of the National Cancer Research Institute [ecancer - News] Delyth is the chief executive of Breast Cancer Now and sits as a cross bench peer in the House of Lords.
Listening To The Voice Of The Patient In Precision Medicine [Forbes] The challenges of pulling together relevant patient information was also a major theme. There were excruciating stories involving efforts to extract data from electronic medical records (EMRs), and from multiple EMRs – and the very high costs incurred when these efforts were successful.
	6.11 Patients
Glastonbury 1, Cancer 0: ‘It's a shame we didn't tick Foo Fighters off the bucket list’ [The Guardian] Inoperable cancer was no reason for my husband to miss the festival.
	6.4 Médico-éco
Cancer Research UK invests £15 million in new major centres [Cancer Research UK] The centres will keep patients at the heart of their work, turning innovation in the laboratory into tangible benefits for patients with cancer. This includes developing more personalised treatments based on growing knowledge of how cancer varies between patients.
How an Oregon cancer institute raised a billion dollars [Nature News & Comment] Gains from two-year fundraising frenzy will aid the early detection of tumours.
	6.6 Publications
No impact without data access [Nature Genetics] A considerable proportion of the usefulness and interest of research publications in our field comes from the data and associated metadata. We therefore insist that data be available for peer reviewers to see and readers to use. Authors should use public permanent repositories designed for appropriately consented data.
	6.7 DMP, Big Data & applis
NHS patient data plans unachievable, review finds |[The Guardian] Major Projects Authority says care.data and NHS Choices schemes have ‘major issues’ with schedule, budget and project definition.